JP2013518112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518112A5 JP2013518112A5 JP2012551252A JP2012551252A JP2013518112A5 JP 2013518112 A5 JP2013518112 A5 JP 2013518112A5 JP 2012551252 A JP2012551252 A JP 2012551252A JP 2012551252 A JP2012551252 A JP 2012551252A JP 2013518112 A5 JP2013518112 A5 JP 2013518112A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- composition
- compound according
- mediated condition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 29
- 230000001404 mediated effect Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- 102000003923 Protein Kinase C Human genes 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 108060006633 protein kinase Proteins 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29865310P | 2010-01-27 | 2010-01-27 | |
| US61/298,653 | 2010-01-27 | ||
| PCT/US2011/022536 WO2011094283A1 (en) | 2010-01-27 | 2011-01-26 | Pyrazolopyridine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013518112A JP2013518112A (ja) | 2013-05-20 |
| JP2013518112A5 true JP2013518112A5 (OSRAM) | 2014-03-06 |
Family
ID=44041755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551252A Withdrawn JP2013518112A (ja) | 2010-01-27 | 2011-01-26 | ピラゾロピリジンキナーゼ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130053395A1 (OSRAM) |
| EP (1) | EP2528916A1 (OSRAM) |
| JP (1) | JP2013518112A (OSRAM) |
| CN (1) | CN103003273A (OSRAM) |
| AU (1) | AU2011209644A1 (OSRAM) |
| CA (1) | CA2787321A1 (OSRAM) |
| MX (1) | MX2012008642A (OSRAM) |
| WO (1) | WO2011094283A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012008642A (es) * | 2010-01-27 | 2012-11-23 | Vertex Pharma | Inhibidores de cinasas de pirazolopiridinas. |
| CN102858769A (zh) * | 2010-01-27 | 2013-01-02 | 沃泰克斯药物股份有限公司 | 吡唑并吡啶激酶抑制剂 |
| ES2851724T3 (es) | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Modulación de células madre |
| EP3185858A4 (en) | 2014-08-25 | 2017-12-27 | University of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| WO2025097025A1 (en) * | 2023-11-03 | 2025-05-08 | Evommune, Inc. | Protein kinase c (pkc) theta inhibitor compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| KR101298951B1 (ko) * | 2004-03-30 | 2013-09-30 | 버텍스 파마슈티칼스 인코포레이티드 | Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한아자인돌 |
| EP1778687A2 (en) * | 2004-07-27 | 2007-05-02 | SGX Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| EP1814883A1 (en) * | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
| ZA200802685B (en) * | 2005-09-30 | 2009-10-28 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| DE102006029447A1 (de) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
| WO2008138834A1 (en) * | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| JP4946728B2 (ja) | 2007-08-23 | 2012-06-06 | 三菱電機株式会社 | 電力増幅器 |
| ES2389992T3 (es) * | 2007-11-02 | 2012-11-05 | Vertex Pharmaceuticals Incorporated | Derivados de [1H-pirazolo[3,4-b]piridin-4-il]-fenilo o -piridin-2-ilo como proteína cinasa c-theta |
| MX2011000843A (es) * | 2008-07-23 | 2011-04-11 | Vertex Pharma | Inhibidores de pirazolopiridin cinasa triciclicos. |
| MX2011000839A (es) * | 2008-07-23 | 2011-04-05 | Vertex Pharma | Inhibidores de pirazolpiridina cinasa. |
| US8569337B2 (en) * | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| JP5542287B2 (ja) * | 2008-07-23 | 2014-07-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピリジンキナーゼ阻害剤 |
| JP5631310B2 (ja) * | 2008-07-23 | 2014-11-26 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 三環式ピラゾロピリジンキナーゼ阻害剤 |
| MX2012008642A (es) * | 2010-01-27 | 2012-11-23 | Vertex Pharma | Inhibidores de cinasas de pirazolopiridinas. |
| CN102858769A (zh) * | 2010-01-27 | 2013-01-02 | 沃泰克斯药物股份有限公司 | 吡唑并吡啶激酶抑制剂 |
-
2011
- 2011-01-26 MX MX2012008642A patent/MX2012008642A/es active IP Right Grant
- 2011-01-26 WO PCT/US2011/022536 patent/WO2011094283A1/en not_active Ceased
- 2011-01-26 CA CA2787321A patent/CA2787321A1/en not_active Abandoned
- 2011-01-26 CN CN2011800073223A patent/CN103003273A/zh active Pending
- 2011-01-26 JP JP2012551252A patent/JP2013518112A/ja not_active Withdrawn
- 2011-01-26 AU AU2011209644A patent/AU2011209644A1/en not_active Abandoned
- 2011-01-26 EP EP11703771A patent/EP2528916A1/en not_active Withdrawn
-
2012
- 2012-07-27 US US13/560,119 patent/US20130053395A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012255759C1 (en) | Kinase inhibitors | |
| JP2013533314A5 (OSRAM) | ||
| JP2013518112A5 (OSRAM) | ||
| JP2008510770A5 (OSRAM) | ||
| JP2015536307A5 (OSRAM) | ||
| JP2015501327A5 (OSRAM) | ||
| JP2012502111A5 (OSRAM) | ||
| JP2014528451A5 (OSRAM) | ||
| JP2012521411A5 (OSRAM) | ||
| JP2013505929A5 (OSRAM) | ||
| WO2008022164A3 (en) | Pyrazine compounds, their use and methods of preparation | |
| JP2014508753A5 (OSRAM) | ||
| JP2013523802A5 (OSRAM) | ||
| JP2013518111A5 (OSRAM) | ||
| JP2020500916A5 (OSRAM) | ||
| JP2019501927A5 (OSRAM) | ||
| JP2011227454A5 (OSRAM) | ||
| JP2015527363A5 (OSRAM) | ||
| JP2020502268A5 (OSRAM) | ||
| US9156789B2 (en) | Process for sorafenib tosylate polymorph III | |
| JP2019516713A5 (OSRAM) | ||
| JP2018521056A5 (OSRAM) | ||
| JP2014505032A5 (OSRAM) | ||
| JP2014505033A5 (OSRAM) | ||
| RU2014145481A (ru) | Циклопропанкарбоксилатные эфиры пуриновых аналогов |